Neurology & Psychiatry · LP-157
Sertraline Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-157Neurology & Psychiatry
- Generic identity
- SertralineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-157
- Generic ingredient
- Sertraline
- Dosage form
- Tablet
- Proposed strength
- 50 mg; 100 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
About Sertraline
Sertraline is a selective serotonin reuptake inhibitor used in defined mental-health conditions. It alters serotonin signalling and is not an immediate sedative. The relevant diagnosis, patient age and other medicines influence treatment selection. Tablets may be used within a wider clinical plan that includes psychological and social support, with follow-up of both benefits and adverse effects.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical contexts include depression and certain anxiety-related or obsessive-compulsive disorders where supported by the local label. A professional should assess symptom severity, functioning, bipolar history, suicide risk and previous treatment response. Improvement is evaluated over time, and persistent symptoms do not justify an unsupervised change. Foreign medicine references may describe uses that differ by jurisdiction; this catalogue does not establish a Luang Pharma authorization for any particular indication.
Important safety considerations
Gastrointestinal effects, headache, sleep disturbance and sexual side effects can occur. Important risks include serotonin syndrome, low sodium, bleeding with interacting medicines and mania in susceptible people. New suicidal thoughts, worsening mood or marked agitation need prompt help. Review monoamine oxidase inhibitors, other serotonergic therapies, anticoagulants and non-steroidal anti-inflammatory drugs. Sudden discontinuation can cause withdrawal symptoms, so stopping or switching should be planned with the treating professional.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The entry lists oral tablets in two strengths. Tablet scoring, excipient composition and suitability for splitting or crushing need confirmation. Oral concentrates or other formulations require separate instructions and are not represented by this tablet record.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review diagnosis, mental-state risks, interacting medicines, liver considerations and follow-up. Match the specific tablet formulation to the prescription and current locally approved information.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Sertraline
- Dosage form / presentation
- Tablet
- Catalogue strength
- 50 mg; 100 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- The 50 mg and 100 mg tablet entries do not establish scoring, coating, crushing suitability, excipients or equivalence to an oral concentrate or another sertraline presentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Sertralinegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-157, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-157.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.